Natroba™ safety starts with a naturally occurring active ingredient.
Unlike the synthetic permethrin found in OTC treatments6, the active ingredient in Natroba™ is spinosad—derived from a naturally occurring soil microorganism.1
What the clinical trials revealed
Natroba™ demonstrated similar or lower treatment related AEs versus the leading OTC medication, Nix® (permethrin 1%).3
No systemic absorption
Spinosad, the active ingredient, was below the level of quantitation (3ng/mL), even in patients as young as six (6) months of age.4
No lab abnormalities
No clinically significant laboratory test results were reported for spinosad. A review of the individual and summary laboratory test results did not identify any safety signal.5
No evidence of neurotoxicity, developmental/reproductive toxicity, immunotoxicity, mutagenicity, or carcinogenicity from spinosad exposure.5
No environmental effects
EPA concludes reasonable certainty that no harm will result to the general population, or to infants and children from aggregate exposure to spinosad residues.5
Nix® is a registered trademark of Prestige Brands, Inc.
- Millar, N. S. & Denholm, I. Nicotinic acetylcholine receptors: targets for commercially important insecticides. Invert. Neurosci. 7, 53-66.
- Natroba Prescribing Information.
- Stough D, Shellabarger S, Quiring J, Gabrielsen A. Efficacy and safety of spinosad and permethrin crème rinses for pediculosis capitis (head lice). Pediatrics. 2009;124(3): e389-395.
- Data on file.
- Federal Register /Vol. 80, No. 248 /Monday, December 28, 2015 /Rules and Regulations.
- CDC-Headlice-Treatment-OTC Medications (8.18.2016). Retrieved from https://www.cdc.gov/parasites/lice/head/treatment.html